Table 1.
Characteristic | EM (n = 29) | IM (n = 51) | PM (n = 9) | P |
---|---|---|---|---|
Median age, years | 49 | 49 | 47 | .587* |
Range | 35-77 | 35-72 | 36-56 | |
Race/ethnicity | .738 | |||
White | 22 | 40 | 6 | |
African American | 4 | 9 | 3 | |
Asian | 1 | 2 | — | |
Hispanic | 2 | — | — | |
Median tamoxifen duration, years | 0.7 | 1.3 | 1.0 | .055* |
Range | 0.3-4.4 | 0.3-5.0 | 0.5-3.0 | |
Menopause | .892 | |||
Pre/peri | 16 | 30 | 4 | |
Post | 13 | 21 | 5 | |
SSRI/SNRI use | .489 | |||
Total | 5 | 16 | 1 | |
Citalopram | 3 | 4 | — | |
Venlafaxine | 1 | 9 | 1 | |
Escitalopram | 1 | 3 | — | |
Reason on tamoxifen | .07 | |||
Invasive carcinoma | 28 | 41 | 9 | |
DCIS | 1 | 10 | — | |
Prior chemotherapy | .041 | |||
Yes | 22 | 27 | 8 | |
No | 7 | 24 | 1 | |
EM | EM/UM = 1; 1.1% | |||
EM/EM = 28; 31.5% | ||||
IM | EM/IM = 20; 22.5% | |||
EM/PM = 19; 21.3% | ||||
IM/IM = 4; 4.5% | ||||
IM/PM = 8; 9.0% | ||||
PM | PM/PM = 9; 10.1% |
Abbreviations: DCIS, ductal carcinoma in situ; EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.
The Kruskal-Wallis test was used to test the shift of location from the median value.